Literature DB >> 9465533

Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis.

M Mahajan1, D Rohatgi, V Talwar, S K Patni, P Mahajan, D S Agarwal.   

Abstract

Twenty patients of tuberculous meningitis (TBM) in age group of 6 months to 10 years included in the study were divided into two groups of 10 patients each. Rifampicin was administered in dosage of 10 mg and 7.5 mg/kg bw to each patient of groups I and II respectively. Drug concentrations in serum and CSF of these patients were measured by a microbiological tube dilution method using a strain of Sarcina lutea. In group I mean serum and CSF concentration was 3.84 micrograms/ml and 0.178 microgram/ml respectively, while in group II it was 2.16 micrograms/ml and 0.206 microgram/ml respectively. These concentrations were many times higher than the MIC against Mycobacterium tuberculosis. Mean percentage penetration of rifampicin in CSF was 5 and 10% in group I and II respectively. We recommend similar studies in large number of children before advocating the therapy with low dose of rifampicin in TBM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9465533

Source DB:  PubMed          Journal:  J Commun Dis        ISSN: 0019-5138


  10 in total

1.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 2.  Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

3.  Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.

Authors:  K W Henry; M C Cruz; S K Katiyar; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 4.  Pharmacokinetics of anti-tuberculosis drugs in children.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; Soumya Swaminathan
Journal:  Indian J Pediatr       Date:  2010-12-17       Impact factor: 1.967

5.  Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.

Authors:  Vincent P DeMarco; Alvaro A Ordonez; Mariah Klunk; Brendan Prideaux; Hui Wang; Zhang Zhuo; Peter J Tonge; Robert F Dannals; Daniel P Holt; Carlton K K Lee; Edward A Weinstein; Véronique Dartois; Kelly E Dooley; Sanjay K Jain
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 6.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

7.  Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Authors:  A Bekker; H S Schaaf; H R Draper; L van der Laan; S Murray; L Wiesner; P R Donald; H M McIlleron; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 8.  Treatment of tuberculous infection and disease in children: the North American perspective.

Authors:  C D Stowe; R F Jacobs
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

9.  A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.

Authors:  Alessandro Schipani; Henry Pertinez; Rachel Mlota; Elizabeth Molyneux; Nuria Lopez; Fraction K Dzinjalamala; Joep J van Oosterhout; Steve A Ward; Saye Khoo; Gerry Davies
Journal:  Br J Clin Pharmacol       Date:  2016-01-30       Impact factor: 4.335

10.  Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.

Authors:  Hendrik Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter Roderick Donald
Journal:  BMC Med       Date:  2009-04-22       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.